Format

Send to

Choose Destination
Bone Marrow Transplant. 2017 Jan;52(1):163-166. doi: 10.1038/bmt.2016.233. Epub 2016 Sep 26.

Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.

Author information

1
Hematology and Bone Marrow Transplantation, Polytechnic University of Marche-Ospedali Riuniti, Ancona, Italy.
2
National Registry GITMO & Data Managing, Ospedale San Martino, Genova, Italy.
3
Hematology Clinic, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU S. Martino-IST, Genova, Italy.
4
Hematology, Department of Cellular Biotechnologies and Hematology, 'Sapienza' University of Rome, Rome, Italy.
5
Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy.
6
Hematology 2 Unit, San Giovanni Battista Hospital and University, Turin, Italy.
7
Hematology and BMT Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy.
8
Department of Hematology, University of Pavia, Policlinico S Matteo-IRCCS, Pavia, Italy.
9
Hematology Department, University of Bari, Bari, Italy.
10
Department of Hematology and Bone Marrow Transplant Unit Ospedale Cervello, Palermo, Italy.
11
Department of Hematology, S Bortolo Hospital, Vicenza, Italy.
12
Institute of Haematology, Università Cattolica Sacro Cuore, Roma, Italy.
13
Haematology Department, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.
14
Hematology - BMT Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
15
Hematology and BMT Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
PMID:
27668760
DOI:
10.1038/bmt.2016.233
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center